LOUISVILLE, Ky. / Feb 23, 2023 / Business Wire / Humana Inc. (NYSE: HUM) announced today that Bruce D. Broussard, President and Chief Executive Officer, will make a presentation to investors at the Cowen Health Care Conference on Tuesday, March 7, 2023, at 9:10 a.m. Eastern time.
A live audio webcast of the presentation will be available via Humana’s Investor Relations page at humana.com. The company suggests webcast participants sign on approximately 15 minutes in advance of the presentation to allow time to run a system test and download any free software needed for access purposes.
About Humana
Humana Inc. (NYSE: HUM) is committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and well-being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large.
To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools – such as in-home care, behavioral health, pharmacy services, data analytics and wellness solutions – combine to produce a simplified experience that makes health care easier to navigate and more effective.
More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at humana.com, including copies of:
Last Trade: | US$286.78 |
Daily Change: | 1.96 0.69 |
Daily Volume: | 1,114,639 |
Market Cap: | US$34.530B |
February 11, 2025 November 12, 2024 October 30, 2024 October 24, 2024 October 23, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load